长江商报消息 ●长江商报记者 沈右荣 信达生物再度与礼来公司签合作协议，共同推进全球创新药研发进程。 牵手全球制药巨头，信达生物（01801.HK）签下了一笔天价出海订单。 2月8日晚，信达生物公告，公司与礼来公司达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。 根据合作协定，信达生物将主导相关项目从药物发现至中国临床概念验证（二期临床试验完成）的研发工作，礼 来获得相关项目在大中华区以外的全球独家开发与商业化许可。 协议约定，信达生物将获得88.5亿美元（约合人民币613亿元）的总付款，包括首付款3.5亿美元、里程碑付款85亿 美元。 成立于2011年的信达生物，2015年就开始与礼来公司开展合作，算上上述协议，二者累计签署了七份合作协议。 高强度研发投入之下，信达生物曾长期亏损，但在2025年，公司经营业绩出现质的变化。2025年上半年，公司实 现的归母净利润为8.34亿元，首次真正实现了盈利。 为了创新药研发，2021年至2024年，信达生物的研发投入合计超过百亿元。 二级市场上，信达生物获得了投资者认可。近一年，公司股价翻倍上涨，目前市值超过千亿元。 第七次与礼来签合作协议 根据最新公告，信达 ...

男生普通话版 下载mp3 女声普通话版 下载mp3 粤语版 下载mp3 西南方言版 下载mp3 东北话版 下载mp3 上海话版 下载mp3 今日优选 美建议美商船远离伊朗领海 白宫哈塞特预告就业转差 美商务部长卢特尼克遭两党施压辞职 24小时内英国首相第二名高级助手辞职 沪深北交易所宣布优化再融资一揽子措施 三部门发布跨境电子商务出口退运商品税收优惠政策 周一，美元指数走势低迷，跌至一周低点，最终收跌0.91%，报96.79；美债收益率普跌，基准的10年期美债收益率收报4.204%，对美联储政策利率敏感的2 年期美债收益率收报3.487%。 在市场等待一系列美国经济数据之际，美元走弱使得以美元计价的大宗商品对海外买家更具吸引力。现货黄金延续涨势，最高触及5086.42美元/盎司，最终 收涨1.93%，报5060.53美元/盎司；现货白银一度触及84美元关口，最终收涨7.17%，报83.37美元/盎司。 国际原油低开高走，因美国警告悬挂美国国旗的船只在霍尔木兹海峡航行时应尽可能远离伊朗水域。WTI原油美盘加速上涨，最终收涨1.45%，报64.45美 元/桶；布伦特原油收涨1.71%，报68.70美元/桶。 美股 ...

◎记者 马嘉悦 "中东、新加坡、欧洲……近一年我频繁飞国外，因为那里有大量配置中国资产的需求。"一位百亿级量 化私募创始人的经历，在私募业颇具代表性。 据私募排排网统计，截至2月9日，当前持有香港9号牌照的内地私募证券投资基金管理人已超130家，较 去年同期增加逾40家。与此同时，多家私募创始人在开年以来与外资的交流中，感受到全球资金增配中 国的意愿逐步增强。 用业内人士的话来说，私募出海从来不仅是扩圈，更是全球资本版图重构下的顺势而为。在这场浪潮 中，中国私募将进一步积聚站在全球舞台的力量。 私募出海趋势已成 135家，是持有香港9号牌照的内地私募证券投资基金管理人最新数字，也是迄今为止的最高数字。 私募排排网最新数据显示，截至2026年2月9日，当前持有香港9号牌照的内地私募证券投资基金管理 人，较去年同期增加了41家。其中，规模在50亿元以上的私募数量达62家，是私募出海的主力军。 "这些年去香港拿9号牌的私募越来越多，有的已经耕耘海外业务多年初见规模，有的则是为了公司未来 的全球规划做准备。"沪上某业内人士感慨称。 灵均投资透露，公司已在香港和新加坡分别设立办公室，作为出海的"桥头堡"，面向境外合格投 ...

高盛相信，信达生物将继续保持其在中国生物技术领域的领先地位，主要得益于拥有大量针对下一代免 疫肿瘤靶点的新型分子，并已获得令人鼓舞的初步数据(如IBI363(PD-1/IL-2α偏向性双特异性抗体)，在 免疫治疗/冷肿瘤中具有差异化的药物特性；强大的商业化能力及与全球合作伙伴，特别是礼来公司的 深度合作等。 高盛发布研报称，信达生物(01801)昨日(8日)宣布与礼来(LLY.US)美元的里程碑付款；及基于中国以外 地区净销售额的分级销售特许权使用费。高盛考虑到当前市场隐含的加权平均资本成本(12%)较高，认 为其目前股价被低估；予该股"买入"评级；基于风险调整后、现金流量折现法，予目标价102.85港元。 信达生物 分时图 日K线 周K线 月K线 85.40 5.90 7.42% 8.18% 5.45% 2.73% 0.00% 2.73% 5.45% 8.18% 73.00 75.17 77.33 79.50 81.67 83.83 86.00 09:30 10:30 12:00/13:00 14:00 16:10 0 31万 62万 94万 ...

Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics Core Insights - Innovent Biologics has entered into its seventh global strategic collaboration with Eli Lilly, focusing on the development of innovative drugs in oncology and immunology, with a deal size that exceeds expectations [1][4] - Innovent will lead the R&D work from drug discovery to Proof of Concept (PoC) in China, while retaining all rights in Greater China, which signifies international recognition of its R&D capabilities [2][5] - The collaboration is expected to strengthen Innovent's financial position through an upfront payment of USD 350 million and potential milestone payments of up to approximately USD 8.5 billion [1][4][6] - The focus on oncology and immunology aligns with Innovent's existing core pipeline, enhancing its overall competitiveness [2][6] Summary by Sections Strategic Collaboration - Innovent and Eli Lilly's collaboration will leverage Innovent's mature antibody technology platform and efficient clinical capabilities, reducing overseas development risks while enhancing efficiency through Lilly's global network [2][5] - The collaboration allows Innovent to lead early-stage R&D and retain rights in Greater China, marking a significant step in the globalization of Chinese innovative biopharmaceutical companies [5][6] Financial Implications - The upfront and milestone payments from the collaboration will provide a financial safety net for Innovent, while sales royalties will enable long-term benefits from global market growth [6] - Management projects that Innovent will achieve revenue of CNY 20 billion by 2027, with five products expected to enter MRCT Phase III clinical stages by 2030 [8] Pipeline and Market Potential - Innovent's oncology pipeline is expected to maintain its core market position, with additional growth drivers from integrated pipelines such as Mazdutide, Tolecimab, and Tetumumab [8] - Three assets, including IBI363, IBI343, and IBI324, are set to advance to global multi-regional Phase III clinical stages, with a combined market potential estimated at USD 60 billion [8]

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly marks the seventh partnership aimed at advancing innovative drugs in oncology and immunology, with Innovent leading the development and retaining rights in Greater China while Eli Lilly secures global rights outside this region [1][2]. Group 1: Financial Aspects - Innovent will receive an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [1]. - Following the announcement, Innovent's stock price surged by 7.42%, closing at HKD 85.40 per share, with a market capitalization of HKD 148.2 billion [2]. Group 2: Strategic Importance - The collaboration is characterized as a pure incremental partnership, focusing on new targets and molecules outside Innovent's existing clinical pipeline [2]. - Innovent's management highlighted the recognition of its R&D capabilities globally and the long-standing relationship with Eli Lilly as key factors for this partnership [2]. Group 3: Historical Context - Previous collaborations between Innovent and Eli Lilly include the development of the PD-1 inhibitor, which became a cornerstone product for Innovent after its launch in 2018 [3]. - Innovent has also introduced the GLP-1 dual receptor agonist from Eli Lilly, which is set to launch in 2025, marking a significant addition to its product portfolio [3]. Group 4: Market Position and Future Plans - Innovent is seen as a leading player in the domestic innovative drug sector, having capitalized on significant targets like PD-1 and GLP-1, which are closely associated with Eli Lilly [2][3]. - The company aims to enter a new phase of dual-driven product lines and internationalization by 2025, with plans to establish a global R&D and commercialization platform [8][9]. - Innovent's goal includes having five pipelines enter global multi-center Phase III clinical trials by 2030, with a revenue target of CNY 20 billion by 2027 [9].

Market Overview - The Dow Jones Industrial Average is projected to reach 100,000 points by January 2029, as stated by Trump, with the index recently surpassing 50,000 points for the first time [1] - The Hong Kong stock market rebounded significantly, closing up 1.76%, while the Nikkei 225 and KOSPI indices rose by 3.89% and 4.10%, respectively [1] - The Japanese ruling coalition secured a majority in the recent elections, with promises to stimulate the economy, leading to a surge in the Japanese stock market [1] Gold and Mining Stocks - Gold stocks continued to rebound, with the WanGuo Gold Group rising over 8% [2] - Zijin Mining announced a three-year production plan aiming to rank among the top three globally in copper and gold production by 2028, resulting in a stock increase of over 5% [2] AI and Technology Sector - Major tech companies including Meta, Amazon, Google, and Microsoft are expected to have a combined capital expenditure of $660 billion this year [3] - Nvidia is anticipated to report strong earnings, with Goldman Sachs raising its price target to $250, indicating a potential 35% upside from last week's closing price [2][3] Renewable Energy and Power Generation - North America is shifting investments in electricity generation from gas turbines to gas internal combustion engines and SOFCs, with stocks like Eagle Precision and Dongfang Electric seeing significant gains [4] - Dongfang Electric announced the commissioning of Ethiopia's largest wind power project, contributing to a stock increase of over 14% [4] AI Applications and Content Creation - ByteDance launched the Seedance 2.0 video generation model, which can create high-quality videos in 60 seconds, positively impacting related stocks like IP reserve holder Yuedong Group, which rose nearly 10% [5] - The copyright technology service provider for short dramas, Fubo Group, also saw a stock increase of over 7% [5] Real Estate Sector - Major real estate companies are undergoing organizational restructuring to adapt to market conditions, with firms like China Overseas Development and China Resources Land implementing significant changes [8] - These strategic adjustments are expected to enhance performance and improve valuations in the sector [8] Entertainment Sector - Cat's Eye Entertainment reported that the pre-sale box office for the 2026 Spring Festival exceeded 60 million yuan, with expectations for strong performance in upcoming films [9] - The company is heavily involved in the production and promotion of major films, which is likely to boost its revenue [9][10]

2月8日，信达生物与礼来达成合作，共同推进肿瘤及免疫领域创新药全球研发，信达生物将获3.5亿美 元首付款及最高约85亿美元里程碑付款及销售分成。 无独有偶，2月5日，复宏汉霖与日本卫材签订协议，授予其在日本区域内斯鲁利单抗注射液用于肿瘤适 应症治疗的开发、生产及商业化权利，交易总金额近4亿美元。 回顾2025年，中国创新药对外授权（License-out）交易总金额突破1300亿美元，中国医药企业的国际化 进程已逐步成为行业当前发展的主旋律。然而，在推动企业"走出去"的实践中，呈现出显著的分层特征 与结构性不均衡。一方面，以华润医药、百济神州、复星医药等为代表的龙头企业已具备较为扎实的国 际化基础；另一方面，大量中小企业则因国内市场竞争高度内卷及集采带来的经营压力，将海外市场视 为新的生存机会与发展路径。 突破核心瓶颈 合规能力是国际化的核心前提。对于原料药、中间体企业而言，过去凭借成本与产能优势尚可维持出 口，但若要进入生物医药、高端医疗器械乃至医保报销体系，则必须满足ICH、PIC/S、FDA、EMA等 国际通行的法规与质量标准。值得肯定的是，中国已正式加入ICH，并正在积极申请加入PIC/S。后者 一旦 ...

来源：新浪基金 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。* 再来看港股通医疗板块表现，AI医疗、脑机接口概念股较为活跃，大权重领衔涨势，京东健康、阿里 健康、平安好医生齐涨3%左右，港股通医疗ETF华宝（159137）日线五连阳。 目前AI医疗在C端的渗透正在加速，从智能问诊到慢病管理的应用场景不断拓展，推动阿里健康、京东 健康等港股互联网医疗平台价值重估。 中信建投证券指出，港股器械整体创新属性较强，部分企业的创新产品具有license-out或被并购的可 能。基本面维度，行业内部多数公司经营业绩持续改善，低估值投资价值凸显。事件方面，预计迈瑞医 疗、可孚医疗今年将在港股上市，港股医疗器械板块效应和投资机会或将增多。* 2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集 ...

2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF（520880）高开后上探2.75%，收涨1.77%成功连阳，一并 站上10日均线，全天成交3.81亿元。 2月8日晚，信达生物公告，公司与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研 发进程。信达将获3.5亿美元首付款，最高可获85亿美元里程碑付款及大中华区以外净销售额梯度分 成。 2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除 信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产 创新药管线的全球价值。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大 ...